{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    17,
    18,
    19,
    21,
    24,
    25,
    26,
    27,
    28,
    32,
    35,
    43
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "7",
        "name": "Amendment 7",
        "scope": {
          "id": "21829185-1050-40dd-858a-a9206ed471af",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "bb35390c-2c5b-4984-b75f-5cb7d89f1856",
          "code": {
            "id": "74c2de04-abfd-4165-b70f-a73ed86889bc",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "9c5c9ff6-f68d-44e8-8fc5-f25e710d69ca",
            "type": {
              "id": "fca13f4d-a699-4cb0-8e72-d14a17bf6c12",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The main purpose of this amendment is to: 1) revise the definition of end of study to include Post-Trial Access (PTA) program i.e rollover protocol or a post study drug supply (PSDS) option for patients still on study treatment and in the opinion of the investigator still deriving clinical benefit at the time of end of the study, 2) update safety information on hemophagocytic lymphohistiocytosis (HLH), and update of 'dose modification and recommended clinical management guidelines' in the safety section including treatment resumption for recurrent grade 4 asymptomatic amylase or lipase elevation per UK Health Authority (MHRA) request.",
        "effectiveDate": "2023-01-27",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3"
        ],
        "previousVersion": "6",
        "newVersion": "7"
      },
      {
        "id": "amend_2",
        "number": "6",
        "name": "Amendment 6",
        "scope": {
          "id": "0e28e01d-2835-4080-b460-b9a2439a75c2",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "4985e372-a3ec-4592-9483-97dbd22d44a4",
          "code": {
            "id": "8e1db249-c123-4598-9924-cdd6c2cdaccd",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "d22781f7-0924-4db7-881c-b0477802acab",
            "type": {
              "id": "96d274a5-e19c-4da4-a5c6-f8f7089bbb8d",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The main reason for preparation of this amendment was to update on primary PFS analysis outcome and provide rationale for continued safety and overall survival follow-up of ongoing patients. It also includes guidance on COVID-19 related challenges, updates contraception requirements based on new Investigator's Brochure data, and mandates unblinding of study treatment for ongoing patients.",
        "effectiveDate": "2020-10-13",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2",
          "ar_2_3"
        ],
        "previousVersion": "5",
        "newVersion": "6"
      },
      {
        "id": "amend_3",
        "number": "5",
        "name": "Amendment 5",
        "scope": {
          "id": "982c4e70-8583-444f-b1f9-f3c9787566cd",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "206b0d9b-6147-4fe6-b526-b1cff40550d1",
          "code": {
            "id": "8e0252fa-a9e1-4af2-a893-5dc2eb74d165",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "7f908de2-ec2f-4ac1-a0a0-62337df908c0",
            "type": {
              "id": "f4d8ba4d-f822-49ad-8c1c-629fa9cd4448",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary objective of this protocol amendment is to adjust the timing of the final PFS analysis and to include an interim analysis for PFS based on revised assumptions on the delayed treatment effect, following observations from the KEYNOTE-022 trial in a similar patient population.",
        "effectiveDate": "2019-03-08",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2"
        ],
        "previousVersion": "4",
        "newVersion": "5"
      },
      {
        "id": "amend_4",
        "number": "4",
        "name": "Amendment 4",
        "scope": {
          "id": "8a5464b4-cd89-4edd-a6b6-2232389dde62",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "713202ba-ae7d-4e45-a0b6-fb755f856a44",
          "code": {
            "id": "0b725294-27d6-4d3e-9cfe-1225504aa2fd",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "f533ce34-264d-44da-8fcb-ce57eb8b7fb0",
            "type": {
              "id": "347969e7-c1cb-448b-b487-e6ff0f48d75f",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary objective of this protocol amendment is to align the contraception requirements during and after study treatment based on the dabrafenib Investigator’s Brochure (IB) Edition 10 and trametinib IB Edition 9. Further, the safety follow-up periods have been aligned with the contraception requirements.",
        "effectiveDate": "2018-08-14",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2",
          "ar_4_3"
        ],
        "previousVersion": "3",
        "newVersion": "4"
      },
      {
        "id": "amend_5",
        "number": "3",
        "name": "Amendment 3",
        "scope": {
          "id": "bb5b6da5-b25f-4973-961b-80586cce8b0d",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "3f55febe-3304-4f51-8680-bb423e76681e",
          "code": {
            "id": "86bc2f37-ff5c-4d44-bd7a-3f5422ba832b",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "8e5b033c-4300-499d-a724-3d966b0de0e7",
            "type": {
              "id": "474cab89-e823-4248-9b3f-82f0df02985a",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary objective of this protocol amendment is to change pyrexia management guidelines based on the safety profile observed in the safety run-in (part 1) and feedback received from investigators upon review of safety data.",
        "effectiveDate": "2017-07-14",
        "reasonIds": [
          "ar_5_1",
          "ar_5_2"
        ],
        "previousVersion": "2",
        "newVersion": "3"
      },
      {
        "id": "amend_6",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "5816dd9f-d21d-4dd6-affd-3a6251c1d97f",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "3cfea6cf-bb8d-4cfa-89a4-33ff7e772b2c",
          "code": {
            "id": "a889c23f-d1a3-44f1-b72b-5fdbd800aea1",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "436313b1-c242-4390-882c-58c1251a72c4",
            "type": {
              "id": "2e8e99b0-d585-4e25-9a93-d9cc545c2caf",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment 2 is required to implement specific feedback received from the U.S. Food and Drug Administration (FDA) and the German Paul-Ehrlich Institute (PEI) and the French health authority ANSM (agence nationale de sécurité du medicament) upon review of the protocol.",
        "effectiveDate": "2017-03-07",
        "reasonIds": [
          "ar_6_1"
        ],
        "previousVersion": "1",
        "newVersion": "2"
      },
      {
        "id": "amend_7",
        "number": "1",
        "name": "Amendment 1",
        "scope": {
          "id": "6d2b86b1-9de2-45f5-acff-a863345c0634",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "b1dd815a-078c-4b8d-bd10-3d33d7fada96",
          "code": {
            "id": "8018d20a-3195-49ac-a787-cebfe0d5754c",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "3b6898c9-95b7-4884-af08-bf9ed35eee21",
            "type": {
              "id": "49be98a2-855b-4b9b-8e27-83a9ca1833a9",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary purpose of this protocol amendment is to clarify that double barrier contraception methods are not classified as highly effective methods, per Clinical Trial Facilitation Group (CTFG) guidelines.",
        "effectiveDate": "2017-01-27",
        "reasonIds": [
          "ar_7_1",
          "ar_7_2"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "1"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_3",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "STATISTICAL",
        "description": "Statistical",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_6_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_7_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_7_2",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_2",
        "name": "Germany",
        "instanceType": "Country",
        "code": "DE"
      },
      {
        "id": "country_3",
        "name": "France",
        "instanceType": "Country",
        "code": "FR"
      },
      {
        "id": "country_4",
        "name": "United Kingdom",
        "instanceType": "Country",
        "code": "GB"
      },
      {
        "id": "country_5",
        "name": "Switzerland",
        "instanceType": "Country",
        "code": "CH"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 7,
      "countryCount": 5,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2",
        "country_3",
        "country_4",
        "country_5"
      ],
      "regions": [
        "North America",
        "Europe"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "7",
        "effectiveDate": "2023-01-27",
        "summary": "The main purpose of this amendment is to: 1) revise the definition of end of study to include Post-Trial Access (PTA) program i.e rollover protocol or a post study drug supply (PSDS) option for patients still on study treatment and in the opinion of the investigator still deriving clinical benefit at the time of end of the study, 2) update safety information on hemophagocytic lymphohistiocytosis (HLH), and update of 'dose modification and recommended clinical management guidelines' in the safety section including treatment resumption for recurrent grade 4 asymptomatic amylase or lipase elevation per UK Health Authority (MHRA) request.",
        "previousVersion": "6",
        "newVersion": "7",
        "reasons": [
          "Operational",
          "Regulatory",
          "Safety"
        ]
      },
      {
        "number": "6",
        "effectiveDate": "2020-10-13",
        "summary": "The main reason for preparation of this amendment was to update on primary PFS analysis outcome and provide rationale for continued safety and overall survival follow-up of ongoing patients. It also includes guidance on COVID-19 related challenges, updates contraception requirements based on new Investigator's Brochure data, and mandates unblinding of study treatment for ongoing patients.",
        "previousVersion": "5",
        "newVersion": "6",
        "reasons": [
          "Scientific",
          "Safety",
          "Operational"
        ]
      },
      {
        "number": "5",
        "effectiveDate": "2019-03-08",
        "summary": "The primary objective of this protocol amendment is to adjust the timing of the final PFS analysis and to include an interim analysis for PFS based on revised assumptions on the delayed treatment effect, following observations from the KEYNOTE-022 trial in a similar patient population.",
        "previousVersion": "4",
        "newVersion": "5",
        "reasons": [
          "Scientific",
          "Statistical"
        ]
      },
      {
        "number": "4",
        "effectiveDate": "2018-08-14",
        "summary": "The primary objective of this protocol amendment is to align the contraception requirements during and after study treatment based on the dabrafenib Investigator’s Brochure (IB) Edition 10 and trametinib IB Edition 9. Further, the safety follow-up periods have been aligned with the contraception requirements.",
        "previousVersion": "3",
        "newVersion": "4",
        "reasons": [
          "Safety",
          "Regulatory",
          "Administrative"
        ]
      },
      {
        "number": "3",
        "effectiveDate": "2017-07-14",
        "summary": "The primary objective of this protocol amendment is to change pyrexia management guidelines based on the safety profile observed in the safety run-in (part 1) and feedback received from investigators upon review of safety data.",
        "previousVersion": "2",
        "newVersion": "3",
        "reasons": [
          "Safety",
          "Operational"
        ]
      },
      {
        "number": "2",
        "effectiveDate": "2017-03-07",
        "summary": "Amendment 2 is required to implement specific feedback received from the U.S. Food and Drug Administration (FDA) and the German Paul-Ehrlich Institute (PEI) and the French health authority ANSM (agence nationale de sécurité du medicament) upon review of the protocol.",
        "previousVersion": "1",
        "newVersion": "2",
        "reasons": [
          "Regulatory"
        ]
      },
      {
        "number": "1",
        "effectiveDate": "2017-01-27",
        "summary": "The primary purpose of this protocol amendment is to clarify that double barrier contraception methods are not classified as highly effective methods, per Clinical Trial Facilitation Group (CTFG) guidelines.",
        "previousVersion": "Original Protocol",
        "newVersion": "1",
        "reasons": [
          "Regulatory",
          "Safety"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "Germany",
          "code": "DE"
        },
        {
          "name": "France",
          "code": "FR"
        },
        {
          "name": "United Kingdom",
          "code": "GB"
        },
        {
          "name": "Switzerland",
          "code": "CH"
        }
      ],
      "regions": [
        "North America",
        "Europe"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}